Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis

被引：0
|
作者：
Sturm, A. [1 ]
Sebastian, S. [2 ]
Faye, A. S. [3 ]
Armuzzi, A. [4 ]
Buisson, A. [5 ]
Halfvarson, J. [6 ]
Zeissig, S. [7 ,8 ]
Kochar, B. [9 ]
Maier, S. [10 ]
Redondo, I [10 ]
Moses, R. E. [10 ]
Keohane, A. [11 ]
Watanabe, K. [12 ]
机构：
[1] DRK Kliniken Berlin Westend, Dept Gastroenterol, Berlin, Germany
[2] Hull Univ Teaching Hosp, IBD Unit, Kingston Upon Hull, England
[3] NYU Langone Hlth, Inflammatory Bowel Dis Ctr, New York, NY USA
[4] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy
[5] Univ Clermont Auvergne, CHU Clermont Ferrand, Serv Hepatogastroenterol, Inserm,3iHP, Clermont Ferrand, France
[6] Orebro Univ, Dept Gastroenterol, Orebro, Sweden
[7] Univ Med Greifswald, Dept Internal Med A, Greifswald, Germany
[8] Tech Univ TU Dresden, Med Fac, Dresden, Germany
[9] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA USA
[10] Eli Lilly & Co, Lilly Immunol, Indianapolis, IN USA
[11] HaaPACS GmbH, Stat Europe, Schriesheim, Germany
[12] Univ Toyama, Dept Internal Med Inflammatory Bowel Dis, Toyama, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.1263
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1089
引用
收藏
页码：i2005 / i2006
页数：2
相关论文
共 50 条
  • [1] Extended Induction of Mirikizumab Sustains Efficacy and Safety Over 104 Weeks for Patients With Moderately to Severely Active Ulcerative Colitis Refractory to Initial Induction
    D'Haens, Geert
    Navabi, Seyedehsan
    Chan-Diehl, Faye
    Moses, Richard E.
    Walter, James
    Gibble, Theresa Hunter
    Laharie, David
    Gisbert, Javier P.
    Vermeire, Severine
    Kobayashi, Taku
    Regueiro, Miguel
    Johns, Jordan
    Charabaty, Aline
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S871 - S872
  • [2] Mirikizumab in moderately to severely active ulcerative colitis: a profile of its use
    Fung, Simon
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2024, : 433 - 443
  • [3] MATCHING-ADJUSTED INDIRECT COMPARISON ON CLINICAL REMISSION FOR MIRIKIZUMAB AND RISANKIZUMAB MAINTENANCE IN THE TREATMENT OF ADULTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
    Siegel, Corey
    Hoque, Sami
    Abreu, Maria
    Zhu, Baojin
    Escobar, Rodrigo
    Redondo, Isabel
    Owen, Charles
    Yang, Chao
    Keohane, Anthony
    Dignass, Axel
    INFLAMMATORY BOWEL DISEASES, 2025, 31 : S10 - S11
  • [4] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
    Sandborn, W. J.
    Ferrante, M.
    Bhandari, B. R.
    Berliba, E.
    Hibi, T.
    D'Haens, G. Geert R.
    Tuttle, J.
    Krueger, K.
    Friedrich, S.
    Durante, M.
    Arora, V.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
  • [5] EXTENDED INDUCTION RESPONSE IN PATIENTS TREATED WITH MIRIKIZUMAB WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT TRIALS
    D'Haens, Geert
    Higgins, Peter D.
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Lee, Scott
    Moses, Richard
    Redondo, Isabel
    Escobar, Rodrigo
    Morris, Nathan
    Kobayashi, Taku
    GASTROENTEROLOGY, 2023, 164 (06) : S1086 - S1086
  • [6] Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials
    D'Haens, G.
    Higgins, P. D. R.
    Peyrin-Biroulet, L.
    Sands, B. E.
    Lee, S.
    Moses, R. E.
    Redondo, I.
    Escobar, R.
    Morris, N.
    Kobayashi, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 682 - 682
  • [7] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S10 - S11
  • [8] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    GASTROENTEROLOGY, 2020, 158 (03) : S17 - S18
  • [9] EFFICACY AND SAFETY OF MIRIKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-2 STUDY
    Dubinsky, Marla C.
    Irving, Peter M.
    Li, Xingyuan
    Howaldt, Stefanie
    Pokrotnieks, Juris
    Krueger, Kathryn A.
    Laskowski, Janelle
    Lissoos, Trevor
    Milata, Joe
    Morris, Nathan
    Arora, Vipin
    Milch, Catherine
    Sands, Bruce E.
    GASTROENTEROLOGY, 2022, 162 (07) : S1393 - S1394
  • [10] Endoscopic and Histologic Remission After 2 Years Treatment With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Margo, Fernando
    Peyrin-Biroulet, Laurent
    Kobayashi, Taku
    Jairath, Vipul
    Walsh, Alissa
    Christensen, Britt
    Wu, Jianmin
    Park, Gina
    Redondo, Isabel
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S812
12345